Cyclopharm Limited (CYC:ASX)
Cyclopharm Limited is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. The Company operates in two business segments: Technegas segment and Molecular imaging segment. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals used by physicians in the detection of cancer, neurological disorders and cardiac diseases. The Company offers Technegas for lung imaging, and Molecular Imaging/Positron Emission Tomography radiopharmaceuticals, which are used in cancer, brain and cardiac imaging. The Company formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Company's Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.